Corporate Website
Africa
Argentina
Asia
Australia
Belgium
Brazil
Bulgaria
Canada (EN)
Chile
China
Denmark
Egypt
France
Germany
Greece
Hungary
Indonesia
Italia
India
Japan
Korea
Malaysia
Mexico
Middle East
Netherlands
Peru
Philippines
Poland
Portugal
Romania
Russia
South Africa
Spain
Sweden
Thailand
Tunisia
Turkey
Ukraine
United Kingdom
USA
Vietnam
Mid-year results >
Ceva attracts strong investor support for 4th LMBO and returns to double-digit growth in first 6 months of 2014
Ceva Santé Animale reorganizes its capital structure to bolster its international ambitions >
Libourne, June 11, 2014: The management of Ceva Santé Animale announces a reshaping of its capital structure through a new round of financing which strengthens its position as majority shareholder and welcomes new investors to support the group in a new phase of development. The new capital structure paves the way to the entry of Temasek who will invest alongside the managementas well as French...
Ceva proposes new respiratory health programs for swine >
Symposium held prior to ESPHM presents benefits of more targeted vaccination
Ceva hosts 2nd. Biotech Innovation day in the US >
Industrial know-how partners emphasize benefits of working together
Co-operation in Hungary to prevent zoonosis >
A conference was held in Budapest to facilitate the control of diseases transmissible from animals to humans
Jérôme-André Gauthier, new Strategy and Business Development Director >
Jérôme-André Gauthier joins the Executive Committee team at Ceva Santé Animale as the new Strategy and Business Development Director, starting January 1st, 2014.
Ceva acquires Sogeval >
Sogeval, a subsidiary of Sofiprotéol, joins veterinary firm Ceva Santé Animale with a view to creating one of the world leaders in veterinary pharmacy.
Ceva launches Fertipig® in Asia >
New product gives swine producers “power with control”
Ceva’s growth continues despite difficult market conditions >
Libourne, France, 22 July, 2013: Consolidated sales of the Ceva Group reached €310m in the first 6 months of 2013, up by 2%, 4.2% on the previous year at a constant perimeter and exchange rates. Ceva recorded solid growth of 9% on a constant basis (constant perimeter and exchange rates), if one excludes 2 factors: Vectra® sales in the United States, which were less than anticipated, due to a...
Ceva signs a Joint-venture agreement in China to help control zoonoses >
Joint-venture with Jinyu Baoling will produce brucellosis vaccines in Inner Mongolia